Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

Rhea-AI Summary

Intellia Therapeutics (Nasdaq: NTLA) will host a conference call and webcast on August 6, 2026 at 8:00 a.m. ET to discuss its second quarter 2026 financial results and business updates. U.S. investors can dial 1-833-316-0545, international participants 1-412-317-5726, and a replay will be accessible for about 90 days via the Events page in the Investors & Media section of Intellia’s website.

Market Context

The peer snapshot showed RCUS at -3.64%, with ELVN and ZYME also lower. That context placed the sche...

Analysis

The peer snapshot showed RCUS at -3.64%, with ELVN and ZYME also lower. That context placed the scheduled update against broader peer weakness, while high short positioning remained a risk to monitor.

Key Figures

Reporting period: Q2 2026 Conference call date: August 6, 2026 Conference call time: 8 a.m. ET

3 metrics

Reporting period Q2 2026 Financial results to be discussed

Conference call date August 6, 2026 Scheduled results and business update call

Conference call time 8 a.m. ET Scheduled call time

Previous Conferences,earnings date Reports

1 past event · Latest: Feb 19 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 19	Earnings call notice	Neutral	+4.5%	Conference call scheduled to discuss fourth-quarter and full-year 2025 results and business updates.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The prior tag-matched conference-call notice was followed by a 4.49% 24-hour gain.

Key Terms

crispr gene editing

1 terms

crispr gene editing technical

"focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies"

CRISPR gene editing is a laboratory technique that uses a guided molecular “scissor” to change DNA at specific locations, allowing scientists to add, remove, or correct genetic code. For investors, it matters because it underpins a new class of therapies and biotech products with high upside if they work, but also carries long development timelines, regulatory uncertainty, and technical risks that can create large swings in company value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates.

To join a webcast of the call, please visit this link. To join the teleconference, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.

A replay of the call will be available for approximately 90 days on the Events page in the Investors & Media section of Intellia’s website, www.intelliatx.com.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com 

FAQ

When is Intellia Therapeutics' (NTLA) Q2 2026 earnings conference call?

Intellia Therapeutics' Q2 2026 earnings conference call is scheduled for August 6, 2026 at 8:00 a.m. ET. According to Intellia Therapeutics, the call will cover second quarter 2026 financial results and provide business updates for investors and analysts.

How can investors access the Intellia Therapeutics (NTLA) Q2 2026 earnings webcast?

Investors can access the Intellia Therapeutics Q2 2026 earnings webcast by visiting the company’s online webcast link. According to Intellia Therapeutics, the webcast will stream the August 6, 2026, 8:00 a.m. ET conference call discussing financial results and business updates.

What phone numbers can be used to join the Intellia Therapeutics (NTLA) August 6, 2026 earnings call?

U.S. callers can join the Intellia Therapeutics earnings call by dialing 1-833-316-0545, while international callers should dial 1-412-317-5726. According to Intellia Therapeutics, participants should call about five minutes early and request connection to the Intellia conference call.

Will a replay be available for the Intellia Therapeutics (NTLA) Q2 2026 earnings conference call?

Yes, a replay of the Q2 2026 earnings conference call will be available for about 90 days. According to Intellia Therapeutics, investors can access this replay on the Events page within the Investors & Media section of the company’s website, www.intelliatx.com.

Where can I find Intellia Therapeutics (NTLA) investor events like the Q2 2026 call?

Investor events such as the Q2 2026 earnings call are listed on Intellia Therapeutics’ website. According to Intellia Therapeutics, the Events page in the Investors & Media section hosts webcast links, access details, and replays for scheduled and past calls.